The processing of EMCV proteins 2A and 2B is a eukaryote-specific, co-translational event that occurs during the elongation phase of translation without requiring eukaryotic release factors.
Answers are grounded in this paper and cite their sources.
Indicates 2A-2B cleavage during eukaryotic elongation; extends mechanistic models but leaves open in vivo relevance and therapeutic implications.
The genomic RNA of encephalomyocarditis virus (EMCV) encodes a single polyprotein, and the primary scission of the polyprotein occurs between nonstructural proteins 2A and 2B by an unknown mechanism. To gain insight into the mechanism of 2A-2B processing, we first translated the 2A-2B region in vitro with eukaryotic and prokaryotic translation systems. The 2A-2B processing occurred only in the eukaryotic systems, not in the prokaryotic systems, and the unprocessed 2A-2B protein synthesized by a prokaryotic system remained uncleaved when incubated with a eukaryotic cell extract. These results suggest that 2A-2B processing is a eukaryote-specific, co-translational event. To define the translation factors required for 2A-2B processing, we constituted a protein synthesis system with eukaryotic elongation factors 1 and 2, eukaryotic release factors 1 and 3 (eRF1 and eRF3), aminoacyl-tRNA synthetases, tRNAs, ribosome subunits, and a plasmid template that included the hepatitis C virus internal ribosome entry site. We successfully reproduced 2A-2B processing in the reconstituted system even without eRFs. Our results indicate that this unusual event occurs in the elongation phase of translation.
No takes yet. Share an insight, caveat, or question.
Machida et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: